Raxibacumab Liquid
NDC Package 49401-080-92
Package Information
Raxibacumab liquids is a bulk ingredient utilized for pharmaceutical compounding or manufacturing. This formulation utilizes a liquid delivery system. Marketed by Glaxosmithkline Llc, this product is identified by NDC 49401-080.
Identification & Billing
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 49401 - Glaxosmithkline Llc
- 49401-080 -
- 49401-080-92 - 7 kg in 1 BAG
- 49401-080 -
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 49401-080-92 identifies a specific commercial package of 7 kg in 1 bag of Raxibacumab (UNFINISHED drug), a bulk ingredient labeled by Glaxosmithkline Llc. This liquid is formulated for use and contains raxibacumab as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Glaxosmithkline Llc on April 09, 2018. The current certification is valid through December 31, 2026.
How is this Glaxosmithkline Llc product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 49401008092. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.